U.S. SECURITIES & EXCHANGE COMMISSION
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
SEC 1474 (3-91)
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section
17(c) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the
Investment Company Act of 1940.
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations
may continue. See Instruction 1(b).
OMB Number 3235-0287
Expires: February 1, 1994
Estimated average burden hours per response . . . . 0.5
1. Name and Address of Reporting Person:
Callaway, Enoch, M.D.
c/o Neurobiological Technologies
1387 Marina Way South
Richmond, CA 94804
2. Issuer Name and Ticker or Trading Symbol:
Neurobiological Technologies, Inc. (NTII)
3. IRS or Social Security Number of Reporting Person (Voluntary):
n/a
4. Statement for Month/Year:
6/96
5. If Amendment, Date of Original (Month/Year):
n/a
6. Relationship of Reporting Person to Issuer (Check All applicable)
Director
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)
Common Stock
2. Transaction Date (Month/Day/Year)
063096
3. Transaction Code (Instr. 8):
B, V
4. Securities Acquired (A) or Disposed of (D) (Instr. 3,4, and 5):
1,598 shares acquired (A) through employee stock purchase plan at price of $2.44
5. Amount of Securities Beneficially Owned at End of Month (Instr. 3 and 4)
79,084
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
I
7. Nature of Indirect Beneficial Ownership (Instr. 4)
By Trust
<PAGE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)
(Line 1) Stock Option (Right to Buy)
(Line 2) Stock Option (Right to Buy)
(Line 3) Stock Option (Right to Buy)
(Line 4) Stock Option (Right to Buy)
(Line 5) Stock Option (Right to Buy)
(Line 6) Stock Option (Right to Buy)
(Line 7) Stock Option (Right to Buy)
(Line 8) Warrant
2. Conversion or Exercise Price of Derivative Security
(Line 1) $3.73
(Line 2) $3.73
(Line 3) $3.73
(Line 4) $3.73
(Line 5) $3.73
(Line 6) $3.73
(Line 7) $3.73
(Line 8) $7.47
3. Transaction Date (Month/Day/Year)
(Line 1) (blank)
(Line 2) (blank)
(Line 3) (blank)
(Line 4) (blank)
(Line 5) (blank)
(Line 6) (blank)
(Line 7) (blank)
(Line 8) (blank)
4. Transaction Code (Instr. 8):
(Line 1) Code A, V
(Line 2) Code A, V
(Line 3) Code A, V
(Line 4) Code A, V
(Line 5) Code A, V
(Line 6) Code A, V
(Line 7) Code A, V
(Line 8) Code A, V
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,4,
and 5)
(Line 1) (blank)
(Line 2) (blank)
(Line 3) (blank)
(Line 4) (blank)
(Line 5) (blank)
(Line 6) (blank)
(Line 7) (blank)
(Line 8) (blank)
6. Date Exercisable and Expiration Date (Month/Day/Year)
6a. Date Exercisable=
(Line 1) 7/90
(Line 2) 2/91
<PAGE>
(Line 3) 1/92
(Line 4) 1/93
(Line 5) 3/93
(Line 6) 12/93
(Line 7) 7/90
(Line 8) 4/92
6b. Expiration Date =
(Line 1) 7/00
(Line 2) 2/01
(Line 3) 1/02
(Line 4) 1/03
(Line 5) 3/03
(Line 6) 12/03
(Line 7) 7/00
(Line 8) 4/97
7. Title and Amount of Underlying Securities (Instr. 3 and 4):
7a. Title
(Line 1) Common Stock
(Line 2) Common Stock
(Line 3) Common Stock
(Line 4) Common Stock
(Line 5) Common Stock
(Line 6) Common Stock
(Line 7) Common Stock
(Line 8) Common Stock
7b. Amount or Number of Shares:
(Line 1) 11,786
(Line 2) 1,071
(Line 3) 1,071
(Line 4) 1,071
(Line 5) 5,357
(Line 6) 1,072
(Line 7) 4,286
(Line 8) 669
8. Price of Derivative Security (Instr. 5)
(Line 1) (blank)
(Line 2) (blank)
(Line 3) (blank)
(Line 4) (blank)
(Line 5) (blank)
(Line 6) (blank)
(Line 7) (blank)
(Line 8) (blank)
9. Number of Derivative Securities Beneficially Owned at End of Month (Instr.
4):
26,383 (total)
10. Ownership Form of Derivative Security; Direct (D) or Indirect (I) (Instr.
4):
(Line 1) D
(Line 2) D
(Line 3) D
(Line 4) D
(Line 5) D
(Line 6) D
(Line 7) D
(Line 8) I
<PAGE>
11. Nature of Indirect Beneficial Ownership (Instr. 4):
(Line 1) n/a
(Line 2) n/a
(Line 3) n/a
(Line 4) n/a
(Line 5) n/a
(Line 6) n/a
(Line 7) n/a
(Line 8) By Trust
Explanation of Responses:
**Intentional misstatements or omissions of facts constitute Federal Criminal
Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If
space provided is insufficient, see Instruction 6 for procedure.
**Signature of Reporting Person:
Shawn Johnsons
Date: July 8, 1996
<PAGE>
U.S. SECURITIES & EXCHANGE COMMISSION
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
SEC 1474 (3-91)
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section
17(c) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the
Investment Company Act of 1940.
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations
may continue. See Instruction 1(b).
OMB Number 3235-0287
Expires: February 1, 1994
Estimated average burden hours per response . . . . 0.5
1. Name and Address of Reporting Person:
Johnson, Jian H.
c/o Neurobiological Technologies, Inc.
1387 Marina Way South
Richmond, CA 94804
2. Issuer Name and Ticker or Trading Symbol:
Neurobiological Technologies, Inc. (NTII)
3. IRS or Social Security Number of Reporting Person (Voluntary):
n/a
4. Statement for Month/Year:
6/96
5. If Amendment, Date of Original (Month/Year):
n/a
6. Relationship of Reporting Person to Issuer (Check All applicable)
Officer
Title: VP, Regulatory Affairs
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)
Common Stock
2. Transaction Date (Month/Day/Year)
063096
3. Transaction Code (Instr. 8):
B, V
4. Securities Acquired (A) or Disposed of (D) (Instr. 3,4, and 5):
193 shares acquired (A) through employee stock purchase plan at a price of $2.44
5. Amount of Securities Beneficially Owned at End of Month (Instr. 3 and 4):
1,091
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4):
D
7. Nature of Indirect Beneficial Ownership (Instr. 4):
n/a
<PAGE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3):
(LINE 1) Stock Option (Right to Buy)
(LINE 2) Stock Option (Right to Buy)
2. Conversion or Exercise Price of Derivative Security:
(LINE 1) $3.73
(LINE 2) $3.73
3. Transaction Date (Month/Day/Year):
(LINE 1) (blank)
(LINE 2) (blank)
4. Transaction Code (Instr. 8): Code=, V
(LINE 1) A, V
(LINE 2) A, V
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,4,
and 5):
(LINE 1) (blank)
(LINE 2) (blank)
6. Date Exercisable and Expiration Date (Month/Day/Year):
6a. Date Exercisable=
(LINE 1) See Note 1 below
(LINE 2) See Note 2 below
6b. Expiration Date =
(LINE 1) 111703
(LINE 2) 111703
7. Title and Amount of Underlying Securities (Instr. 3 and 4):
7a. Title:
(LINE 1) Common Stock
(LINE 2) Common Stock
7b. Amount or Number of Shares:
(LINE 1) 8,572
(LINE 2) 18,214
8. Price of Derivative Security (Instr. 5):
(LINE 1) (blank)
(LINE 2) (blank)
9. Number of Derivative Securities Beneficially Owned at End of Month (Instr.
4):
26,786 (total)
10. Ownership Form of Derivative Security; Direct (D) or Indirect (I) (Instr.
4):
(LINE 1) D
(LINE 2) D
11. Nature of Indirect Beneficial Ownership (Instr. 4):
(LINE 1) n/a
(LINE 2) n/a
Explanation of Responses:
<PAGE>
Note 1: The right to exercise this option vests over a four year period from
the date of grant, becoming fully vested in September 1996.
Note 2: The right to exercise this option vests from the date of grant with
respect to 12.5% of the shares covered by this option and the remainder
of the shares vest monthly thereafter for four years from the date of
grant.
**Intentional misstatements or omissions of facts constitute Federal Criminal
Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed.
If space provided is insufficient, see Instruction 6 for procedure.
**Signature of Reporting Person: Shawn Johnsons
Date: July 8, 1996
<PAGE>
U.S. SECURITIES & EXCHANGE COMMISSION
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
SEC 1474 (3-91)
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section
17(c) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the
Investment Company Act of 1940.
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations
may continue. See Instruction 1(b).
OMB Number 3235-0287
Expires: February 1, 1994
Estimated average burden hours per response . . . . 0.5
1. Name and Address of Reporting Person:
Price, Jeffery S.
c/o Neurobiological Technologies
1387 Marina Way South
Richmond CA 94804
2. Issuer Name and Ticker or Trading Symbol:
Neurobiological Technologies, Inc. (NTII)
3. IRS or Social Security Number of Reporting Person (Voluntary):
(blank)
4. Statement for Month/Year:
6/96
5. If Amendment, Date of Original (Month/Year):
n/a
6. Relationship of Reporting Person to Issuer (Check All applicable):
Director, and Officer: President & Chief Executive Officer
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3):
Common Stock
2. Transaction Date (Month/Day/Year):
063096
3. Transaction Code (Instr. 8):
B, V
4. Securities Acquired (A) or Disposed of (D) (Instr. 3,4, and 5):
717 shares Acquired (A) through employee stock purchase plan at a price of $2.44
5. Amount of Securities Beneficially Owned at End of Month (Instr. 3 and 4):
4,503
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4):
D
7. Nature of Indirect Beneficial Ownership (Instr. 4):
n/a
<PAGE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3):
(LINE 1) Stock Option (Right to Buy)
(LINE 2) Stock Option (Right to Buy)
(LINE 3) Stock Option (Right to Buy)
(LINE 4) Stock Option (Right to Buy)
(LINE 5) Stock Option (Right to Buy)
2. Conversion or Exercise Price of Derivative Security:
(LINE 1) $2.875
(LINE 2) $2.875
(LINE 3) $3.73
(LINE 4) $3.73
(LINE 5) $3.73
3. Transaction Date (Month/Day/Year):
(LINE 1) (blank)
(LINE 2) (blank)
(LINE 3) (blank)
(LINE 4) (blank)
(LINE 5) (blank)
4. Transaction Code (Instr. 8):
(LINE 1) A, V
(LINE 2) A, V
(LINE 3) A, V
(LINE 4) A, V
(LINE 5) A, V
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,4,
and 5):
(LINE 1) (blank)
(LINE 2) (blank)
(LINE 3) (blank)
(LINE 4) (blank)
(LINE 5) (blank)
6. Date Exercisable and Expiration Date (Month/Day/Year):
6a. Date Exercisable=
(LINE 1) See Note 1
(LINE 2) See Note 2
(LINE 3) See Note 3
(LINE 4) See Note 4
(LINE 5) See Note 5
6b. Expiration Date =
(LINE 1) 123104
(LINE 2) 123104
(LINE 3) 10/00
(LINE 4) 10/00
(LINE 5) 11/03
7. Title and Amount of Underlying Securities (Instr. 3 and 4):
7a. Title:
(LINE 1) Common Stock
(LINE 2) Common Stock
<PAGE>
(LINE 3) Common Stock
(LINE 4) Common Stock
(LINE 5) Common Stock
7b. Amount or Number of Shares=
(LINE 1) 11,000
(LINE 2) 22,000
(LINE 3) 53,573
(LINE 4) 24,643
(LINE 5) 136,076
8. Price of Derivative Security (Instr. 5):
(LINE 1) (blank)
(LINE 2) (blank)
(LINE 3) (blank)
(LINE 4) (blank)
(LINE 5) (blank)
9. Number of Derivative Securities Beneficially Owned at End of Month (Instr.
4):
247,292 total
10. Ownership Form of Derivative Security; Direct (D) or Indirect (I) (Instr.
4):
(LINE 1) D
(LINE 2) D
(LINE 3) D
(LINE 4) D
(LINE 5) D
11. Nature of Indirect Beneficial Ownership (Instr. 4):
(LINE 1) n/a
(LINE 2) n/a
(LINE 3) n/a
(LINE 4) n/a
(LINE 5) n/a
Explanation of Responses:
Note 1: Vests 1/3 on each of 7/1/95 and 7/1/96 and 7/1/97.
Note 2: 12/31/04, unless earlier accelerated
Note 3: The right to exercise this option vests over a five-year period,
becoming fully vested in October 1995.
Note 4: This right to exercise
this option vests over a five-year period from the date of grant,
becoming fully vested in October 1995.
Note 5: This right to exercise this option vests six months from the date of
grant with respect to 12.5% of the shares covered by this option, and
the remainder of the shares vests monthly thereafter for a period of
four years from the date of grant.
**Intentional misstatements or omissions of facts constitute Federal Criminal
Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed.
If space provided is insufficient, see Instruction 6 for procedure.
**Signature of Reporting Person:
Shawn Johnson
Date: July 8, 1996
<PAGE>
U.S. SECURITIES & EXCHANGE COMMISSION
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
SEC 1474 (3-91)
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section
17(c) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the
Investment Company Act of 1940.
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations
may continue. See Instruction 1(b).
OMB Number 3235-0287
Expires: February 1, 1994
Estimated average burden hours per response . . . . 0.5
1. Name and Address of Reporting Person:
Ostrach, Michael S.
c/o Neurobiological Technologies
1387 Marina Way South
Richmond, CA 94804
2. Issuer Name and Ticker or Trading Symbol:
Neurobiological Technologies, Inc. (NTII)
3. IRS or Social Security Number of Reporting Person (Voluntary):
(blank)
4. Statement for Month/Year:
6/96
5. If Amendment, Date of Original (Month/Year):
n/a
6. Relationship of Reporting Person to Issuer (Check All applicable):
Director, and Officer: Executive VP & Chief Operating Officer
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3):
Common Stock
2. Transaction Date (Month/Day/Year):
063096
3. Transaction Code (Instr. 8):
B, V
4. Securities Acquired (A) or Disposed of (D) (Instr. 3,4, and 5):
615 shares Acquired (A) through employee stock purchase plan at a price of $2.44
5. Amount of Securities Beneficially Owned at End of Month (Instr. 3 and 4):
3,366
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4):
D
7. Nature of Indirect Beneficial Ownership (Instr. 4):
n/a
<PAGE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3):
(LINE 1) Stock Option (Right to Buy)
(LINE 2) Stock Option (Right to Buy)
(LINE 3) Stock Option (Right to Buy)
2. Conversion or Exercise Price of Derivative Security:
(LINE 1) $2.875
(LINE 2) $2.875
(LINE 3) $6.125
3. Transaction Date (Month/Day/Year):
(LINE 1) (blank)
(LINE 2) (blank)
(LINE 3) (blank)
4. Transaction Code (Instr. 8):
(LINE 1) A, V
(LINE 2) A, V
(LINE 3) A, V
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,4,
and 5):
(LINE 1) (blank)
(LINE 2) (blank)
(LINE 3) (blank)
6. Date Exercisable and Expiration Date (Month/Day/Year):
6a. Date Exercisable=
(LINE 1) See Note 1
(LINE 2) See Note 2
(LINE 3) See Note 3
6b. Expiration Date =
(LINE 1) 123104
(LINE 2) 123104
(LINE 3) 060104
7. Title and Amount of Underlying Securities (Instr. 3 and 4):
7a. Title =
(LINE 1) Common Stock
(LINE 2) Common Stock
(LINE 3) Common Stock
7b. Amount or Number of Shares =
(LINE 1) 7,000
(LINE 2) 14,000
(LINE 3) 125,000
8. Price of Derivative Security (Instr. 5):
(LINE 1) (blank)
(LINE 2) (blank)
(LINE 3) (blank)
9. Number of Derivative Securities Beneficially Owned at End of Month (Instr.
4):
146,000 total
<PAGE>
10. Ownership Form of Derivative Security; Direct (D) or Indirect (I) (Instr.
4):
(LINE 1) D
(LINE 2) D
(LINE 3) D
11. Nature of Indirect Beneficial Ownership (Instr. 4):
(LINE 1) n/a
(LINE 2) n/a
(LINE 3) n/a
Explanation of Responses:
Note 1: Vests 1/3 on each of 7/1/95, 7/1/96, and 7/1/97.
Note 2: 12/31/04, unless earlier accelerated
Note 3: The right to exercise this option vested in December 1994 with
respect to 12.5% of the shares covered by this option, and thereafter,
the remainder vests monthly through June 1998.
**Intentional misstatements or omissions of facts constitute Federal Criminal
Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If
space provided is insufficient, see Instruction 6 for procedure.
**Signature of Reporting Person:
Shawn Johnson
Date: July 8, 1996
<PAGE>
U.S. SECURITIES & EXCHANGE COMMISSION
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
SEC 1474 (3-91)
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section
17(c) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the
Investment Company Act of 1940.
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations
may continue. See Instruction 1(b).
OMB Number 3235-0287
Expires: February 1, 1994
Estimated average burden hours per response . . . . 0.5
1. Name and Address of Reporting Person:
Khosrovi, Behzad, Ph.D.
c/o Neurobiological Technologies, Inc.
1387 Marina Way South
Richmond, CA 94804
2. Issuer Name and Ticker or Trading Symbol:
Neurobiological Technologies, Inc. (NTII)
3. IRS or Social Security Number of Reporting Person (Voluntary):
(blank)
4. Statement for Month/Year:
6/96
5. If Amendment, Date of Original (Month/Year):
n/a
6. Relationship of Reporting Person to Issuer (Check All applicable):
Officer: VP, Pharmaceuticals Development
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3):
Common Stock
2. Transaction Date (Month/Day/Year):
063096
3. Transaction Code (Instr. 8):
B, V
4. Securities Acquired (A) or Disposed of (D) (Instr. 3,4, and 5):
1,281 shares Acquired (A) through employee stock purchase plan at a price of
$2.44
5. Amount of Securities Beneficially Owned at End of Month (Instr. 3 and 4):
5,520
6. Ownership Form:
D
7. Nature of Indirect Beneficial Ownership (Instr. 4):
n/a
<PAGE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3):
(LINE 1) Stock Option (Right to Buy)
(LINE 2) Stock Option (Right to Buy)
(LINE 3) Stock Option (Right to Buy)
(LINE 4) Stock Option (Right to Buy)
2. Conversion or Exercise Price of Derivative Security:
(LINE 1) $2.875
(LINE 2) $2.875
(LINE 3) $3.73
(LINE 4) $3.73
3. Transaction Date (Month/Day/Year):
(LINE 1) (blank)
(LINE 2) (blank)
(LINE 3) (blank)
(LINE 4) (blank)
4. Transaction Code (Instr. 8):
(LINE 1) A, V
(LINE 2) A, V
(LINE 3) A, V
(LINE 4) A, V
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,4,
and 5):
(LINE 1) (blank)
(LINE 2) (blank)
(LINE 3) (blank)
(LINE 4) (blank)
6. Date Exercisable and Expiration Date (Month/Day/Year):
6a. Date Exercisable =
(LINE 1) See Note 1
(LINE 2) See Note 2
(LINE 3) See Note 3
(LINE 4) See Note 4
6b. Expiration Date =
(LINE 1) 123104
(LINE 2) 123104
(LINE 3) 2/02
(LINE 4) 11/03
7. Title and Amount of Underlying Securities (Instr. 3 and 4):
7a. Title =
(LINE 1) Common Stock
(LINE 2) Common Stock
(LINE 3) Common Stock
(LINE 4) Common Stock
7b. Amount or Number of Shares:
(LINE 1) 3,000
(LINE 2) 6,000
(LINE 3) 20,367
<PAGE>
(LINE 4) 71,788
8. Price of Derivative Security (Instr. 5):
(LINE 1) (blank)
(LINE 2) (blank)
(LINE 3) (blank)
(LINE 4) (blank)
9. Number of Derivative Securities Beneficially Owned at End of Month (Instr.
4):
101,155 total
10. Ownership Form of Derivative Security; Direct (D) or Indirect (I) (Instr.
4):
(LINE 1) D
(LINE 2) D
(LINE 3) D
(LINE 4) D
11. Nature of Indirect Beneficial Ownership (Instr. 4):
(LINE 1) n/a
(LINE 1) n/a
(LINE 1) n/a
(LINE 1) n/a
Explanation of Responses:
Note 1: Vests 1/3 on each of 7/1/95, 7/1/96, and 7/1/97
Note 2: 12/31/04, unless earlier accelerated
Note 3: The right to exercise this option vests over a four-year period from
the date of grant, becoming fully vested in March 1996.
Note 4: The right to exercise this option vests six months from the date of
grant with respect to 12.5% of the shares covered by this option and
the remainder of the shares vests monthly thereafter for four years
from the date of the grant.
**Intentional misstatements or omissions of facts constitute Federal Criminal
Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If
space provided is insufficient, see Instruction 6 for procedure.
**Signature of Reporting Person:
Shawn Johnson
Date: July 8, 1996
<PAGE>
U.S. SECURITIES & EXCHANGE COMMISSION
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
SEC 1474 (3-91)
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section
17(c) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the
Investment Company Act of 1940.
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations
may continue. See Instruction 1(b).
OMB Number 3235-0287
Expires: February 1, 1994
Estimated average burden hours per response . . . . 0.5
1. Name and Address of Reporting Person:
Yee, Calvert Y.
c/o Neurobiological Technologies
1387 Marina Way South
Richmond, CA 94804
2. Issuer Name and Ticker or Trading Symbol:
Neurobiological Technologies, Inc. (NTII)
3. IRS or Social Security Number of Reporting Person (Voluntary):
(blank)
4. Statement for Month/Year:
6/96
5. If Amendment, Date of Original (Month/Year):
n/a
6. Relationship of Reporting Person to Issuer (Check All applicable):
Officer: VP, Operations and Administration
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3):
Common Stock
2. Transaction Date (Month/Day/Year):
063096
3. Transaction Code (Instr. 8):
B, V
4. Securities Acquired (A) or Disposed of (D) (Instr. 3,4, and 5):
923 shares Acquired (A) through employee stock purchase plan at a price of $2.44
5. Amount of Securities Beneficially Owned at End of Month (Instr. 3 and 4):
3,964 total
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4):
D
7. Nature of Indirect Beneficial Ownership (Instr. 4):
n/a
<PAGE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3):
(LINE 1) Stock Option (Right to Buy)
(LINE 2) Stock Option (Right to Buy)
(LINE 3) Stock Option (Right to Buy)
(LINE 4) Stock Option (Right to Buy)
2. Conversion or Exercise Price of Derivative Security:
(LINE 1) $2.875
(LINE 2) $2.875
(LINE 3) $3.73
(LINE 4) $3.73
3. Transaction Date (Month/Day/Year):
(LINE 1) (blank)
(LINE 2) (blank)
(LINE 3) (blank)
(LINE 4) (blank)
4. Transaction Code (Instr. 8):
(LINE 1) A, V
(LINE 2) A, V
(LINE 3) A, V
(LINE 4) A, V
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,4,
and 5):
(LINE 1) (blank)
(LINE 2) (blank)
(LINE 3) (blank)
(LINE 4) (blank)
6. Date Exercisable and Expiration Date (Month/Day/Year)
6a. Date Exercisable=
(LINE 1) See Note 1
(LINE 2) See Note 2
(LINE 3) See Note 3
(LINE 4) See Note 4
6b. Expiration Date =
(LINE 1) 123104
(LINE 2) 123104
(LINE 3) 2/01
(LINE 4) 11/03
7. Title and Amount of Underlying Securities (Instr. 3 and 4):
7a. Title:
(LINE 1) Common Stock
(LINE 2) Common Stock
(LINE 3) Common Stock
(LINE 4) Common Stock
7b. Amount or Number of Shares:
(LINE 1) 3,000
(LINE 2) 6,000
(LINE 3) 21,429
<PAGE>
(LINE 4) 70,716
8. Price of Derivative Security (Instr. 5):
(LINE 1) (blank)
(LINE 2) (blank)
(LINE 3) (blank)
(LINE 4) (blank)
9. Number of Derivative Securities Beneficially Owned at End of Month (Instr.
4):
101,145 total
10. Ownership Form of Derivative Security; Direct (D) or Indirect (I) (Instr.
4):
(LINE 1) D
(LINE 2) D
(LINE 3) D
(LINE 4) D
11. Nature of Indirect Beneficial Ownership (Instr. 4):
(LINE 1) n/a
(LINE 2) n/a
(LINE 3) n/a
(LINE 4) n/a
Explanation of Responses:
Note 1: Vests 1/3 on each of 7/1/95 and 7/1/96 and 7/1/97.
Note 2: 12/31/04, unless earlier accelerated
Note 3: The right to exercise this option vests over a five year period from
the date of grant, becoming fully vested in March 1996.
Note 4: The right to exercise this option vests six months from the date of
grant with respect to 12.5% of the shares covered by this option, and
the remainder of the shares vests monthly thereafter for a period of
four years from the date of grant.
**Intentional misstatements or omissions of facts constitute Federal Criminal
Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If
space provided is insufficient, see Instruction 6 for procedure.
**Signature of Reporting Person:
Shawn Johnson
Date: July 8, 1996
<PAGE>
U.S. SECURITIES & EXCHANGE COMMISSION
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
SEC 1474 (3-91)
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section
17(c) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the
Investment Company Act of 1940.
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations
may continue. See Instruction 1(b).
OMB Number 3235-0287
Expires: February 1, 1994
Estimated average burden hours per response . . . . 0.5
1. Name and Address of Reporting Person:
Johnson, Shawn
c/o Neurobiological Technologies, Inc.
1387 Marina Way South
Richmond, CA 94804
2. Issuer Name and Ticker or Trading Symbol:
Neurobiological Technologies, Inc. (NTII)
3. IRS or Social Security Number of Reporting Person (Voluntary):
n/a
4. Statement for Month/Year:
6/96
5. If Amendment, Date of Original (Month/Year):
n/a
6. Relationship of Reporting Person to Issuer (Check All applicable):
Officer: Director of Finance
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3):
Common Stock
2. Transaction Date (Month/Day/Year)
063096
3. Transaction Code (Instr. 8):
B, V
4. Securities Acquired (A) or Disposed of (D) (Instr. 3,4, and 5):
1,568 shares acquired (A) through employee stock purchase plan at a price of
$3.19
5. Amount of Securities Beneficially Owned at End of Month (Instr. 3 and 4):
1,568
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4):
D
7. Nature of Indirect Beneficial Ownership (Instr. 4):
n/a
<PAGE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3):
Option to Purchase Common Stock (Right to Buy)
2. Conversion or Exercise Price of Derivative Security
$5.00
3. Transaction Date (Month/Day/Year)
(blank)
4. Transaction Code (Instr. 8):
A, V
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,4,
and 5)
(blank)
6. Date Exercisable and Expiration Date (Month/Day/Year)
Date Exercisable= See Note 1
Expiration Date = 080105
7. Title and Amount of Underlying Securities (Instr. 3 and 4):
Title = Common Stock
Amount or Number of Shares = 20,000
8. Price of Derivative Security (Instr. 5)
(blank)
9. Number of Derivative Securities Beneficially Owned at End of Month (Instr.
4):
20,000
10. Ownership Form of Derivative Security:
Direct (D)
11. Nature of Indirect Beneficial Ownership (Instr. 4):
n/a
Explanation of Responses:
Note 1: The right to exercise this option vests six months from the date of
grant with respect to 12.5% of the shares covered by this option and
and the remainder of the shares vest monthly thereafter four years from
the date of grant.
**Intentional misstatements or omissions of facts constitute Federal Criminal
Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If
space provided is insufficient, see Instruction 6 for procedure.
**Signature of Reporting Person:
Shawn Johnson
Date: July 8, 1996
